Design and quality considerations for randomized controlled trials in systemic sclerosis

Area of Science:

• Rheumatology
• Clinical Trial Methodology
• Systemic Sclerosis Research

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease requiring rigorous clinical trial evaluation.
• Assessing the quality of randomized controlled trials (RCTs) is essential for interpreting treatment efficacy.
• Previous studies highlight variability in SSc trial design and reporting standards.

Purpose of the Study:

• To systematically appraise RCTs for systemic sclerosis (SSc).
• To determine if study design parameters and quality influence reported intervention efficacy.
• To identify areas for improvement in SSc clinical trial methodology.

Main Methods:

• Systematic review and appraisal of 70 randomized controlled trials (RCTs) conducted between 1965 and 2000.
• Analysis of trial design features, patient characteristics, outcome reporting, and results.
• Evaluation of methodological quality indicators including blinding, randomization, allocation concealment, and withdrawals.

Main Results:

• Median sample size was small (28 patients); only 16 trials specified randomization mode, and 7 described allocation concealment.
• Larger trials with longer follow-up generally had higher quality but also higher withdrawal rates.
• Significant efficacy was less likely reported in double-blind studies (P=0.029) and those with higher withdrawal rates (P=0.032).

Conclusions:

• Significant improvements are needed in the design and conduct of SSc RCTs.
• There is a need for adequately powered trials with extended follow-up periods and clearly defined outcomes.
• Enhancing methodological rigor in SSc clinical trials is essential for reliable evidence generation.